Detection of Ultralow-Frequency ctDNA Mutations Using a Dual Hairpin-Competition CRISPR/Cas14a System.
A new genetic test detects cancer DNA in blood 250 times better than before, making early cancer detection possible with standard equipment.
A novel dual hairpin-competition CRISPR/Cas14a (DHCC) platform achieves ctDNA detection at 0.002% variant allele frequency — a 250-fold improvement over prior Cas14a methods and substantially below the practical threshold of ddPCR — through two sequential hairpin layers that dramatically suppress wild-type background. Clinical validation using 22 plasma samples demonstrated 100% concordance with ddPCR for EGFR L858R detection while running on standard qPCR equipment, making ultrasensitive liquid biopsy accessible without specialized infrastructure.
What the study was
- Study design
- Analytical method development with clinical validation
- Population
- Plasma ctDNA from cancer patients (clinical validation n=22 for EGFR L858R)
- Sample size
- 22
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Analytical Chemistry
Why it surfaced
Truly novel CRISPR-based ctDNA sensitivity (0.002% VAF) on standard qPCR instruments could democratize ultrasensitive liquid biopsy. Flag EARLY_CANCER_DETECTION auto-elevates to HIGH. Clinical validation is small (n=22) and exploratory — larger studies needed before clinical implementation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.